Dan W. Reynolds, PhD
Dan W. Reynolds, PhD, is a research investigator II in the chemical development analytical sciences department at GlaxoSmithKline, Five Moor Dr., PO Box 13398, Research Triangle Park, NC 27709.
Articles
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Dan W. Reynolds, PhD;Karen M. Alsante, PhD;Kevin L. Facchine, PhD;June F. Mullaney, PhD;Michael G. Motto, PhD;Todd D. Hatajik
February 1st 2002Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: October 28th 2024 | Updated: November 22nd 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 6th 2024 | Updated: November 22nd 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 22nd 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 22nd 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
